NYBCe and CZ Biohub will derive iPSC lines from cord blood's immune cells, creating shared, broadly compatible resources for cell therapy, disease modelling, and AI-driven drug development.

2026年4月17日，北京大学博雅讲席教授、昌平实验室领衔科学家、生命科学学院邓宏魁课题组在国际学术期刊《细胞》（Cell）上发表了题为“p53 safeguards chemical reprogramming of human somatic cells toward pluripotency”的研究论文。该研究发现，关键肿瘤抑制因子p53在化学重编程中发挥核心保护作用，打破了“p53阻碍细胞 ...

New York Blood Center Enterprises’ (NYBCe) Lindsley F. Kimball Research Institute (LFKRI) today announced a scientific collaboration with Biohub to develop optimized methodologies for deriving induced ...

Cancer incidence rises sharply with age, yet the biological mechanisms that make older patients more vulnerable to treatment failure remain poorly ...

This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American NEW YORK—Despite a cloud of regulatory ...

A clinical trial to reverse age-related vision conditions using stem cell treatment could finally deliver on the promise of a ...

An international team of researchers has shown that NFIX, a protein that regulates neuronal stem cell activity (NSC), also has a role in driving NSC differentiation toward oligodendrocytes, a type of ...

Years before he conducted the research that would earn him a Nobel Prize in Physiology and Medicine, Shinya Yamanaka, MD, ...

Aside from reprogramming and transdifferentiation, the longer-existing approach to generating neurons and NSCs has been differentiating them from pluripotent cells, initially from embryonic stem cells ...